Search Results - "Yazilitas, D"

Interest in STEM among children with a low socio-economic status: further support for the STEM-CIS-instrument through the adapted Dutch STEM-LIT measuring instrument by Grimmon, A. S., Cramer, J., Yazilitas, D., Smeets, I., De Bruyckere, P.

“…When in 2014 the STEM Career Interest Survey (STEM-CIS) was developed, the researchers could check this instrument with other target audiences. Also, the…”
Get full text

The postmodern perfectionist, the pragmatic hedonist and the materialist maximalist: understanding high school students' profile choices towards or away from mathematics, science and technology (MST) fields in the Netherlands by Yazilitas, D., Saharso, S., de Vries, G.C., Svensson, J.S.

“…This study focuses on high school students' profile choices and the choice for or against the Nature and Technology (NT) profile in the Netherlands. A…”
Get full text

3223 The comparison of early stage primary nodal and extranodal diffuse large cell lymphomas: Clinical features, treatment and survival outcomes by Yildirim, N, Hocazade, C, Bozkaya, Y, Yazic, O, Sendur, M.A.N, Yazilitas, D, Serife, T, Arslan, S, Zengin, N

Get full text

2350 The efficacy and predictive factors of response of second line triplet (modified-EOX; epirubicin-oxaliplatin-capacitabine) regimen in metastatic gastric cancer by Sendur, M.A.N, Ozdemir, N, Aksoy, S, Yazici, O, Yazilitas, D, Akinci, M.B, Dede, D.S, Yalcin, B, Zengin, N

Get full text

3238 The effect of “international prognostic index (IPI)” in the determination of prognosis of early stage diffuse large b cell non-hodgkin lymphoma: Is it enough? by Yildirim, N, Yazici, O, Hocazade, C, Bozkaya, Y, Sendur, M.A.N, Akinci, B, Silay, K, Yazilitas, D, Topbaş, S, Zengin, N

Get full text

Accessory spleen hypertrophy mimicking colon cancer metastasis by Ates, I, Yazici, O, Yazilitas, D, Ozdemir, N, Zengin, N

“…Accessory spleen is a congenital form of an ectopic splenic tissue. In this report, we present a case of a patient who was followed with the diagnosis of…”
Get more information

2395 The importance of thiol/disulphide homeostasis in patients with advanced gastric cancer (AGC) receiving modified docetaxel and cisplatin plus fiuorouracil (mDCF) regimen by Yazici, O, Ozdemir, N, Erel, O, Demirci, N.S, Aksoy, S, Sendur, M.A.N, Dogan, M, Yazilitas, D, Erdem, G.U, Neselioglu, S, Hocazade, C, Bozkaya, Y, Bal, O, Zengin, N

Get full text

Comparison the efficacy of second-line modified EOX (epirubicin, oxaliplatin, and capecitabine) and irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) regimens in metastatic gastric cancer patients that progressed on first-line modified docetaxel and cisplatin plus fluorouracil (DCF) regimen by Sendur, Mehmet Ali Nahit, Ozdemir, Nuriye, Özatlı, Tahsin, Yazıcı, Ozan, Aksoy, Sercan, Ekinci, Ahmet Şiyar, Yazılıtaş, Doğan, Günaydın, Yusuf, Oksuzoglu, Berna, Benekli, Mustafa, Zengin, Nurullah

“…Gastric cancer is often diagnosed in advanced stage. Palliative chemotherapy or best supportive care is recommended for patients with metastatic gastric…”
Get full text

The Effect of C-Reactive Protein/Lymphocyte Ratio (CLR) on PFS in Metastatic Breast Cancer Patients Treated with CDK4/6 Inhibitors: A Novel Biomarker by Buyukbayram, Mehmet Emin, Hannarici, Zekeriya, Duzkopru, Yakup, Turhan, Aykut, Caglar, Alperen Akansel, Coban Esdur, Pınar, Bilici, Mehmet, Tekin, Salim Basol, Yazılıtaş, Doğan

“…Hormone positive breast cancer is a tumor with high mortality. Combining antihormonal therapy with cyclin dependent kinase 4/6 inhibitors (CDK4/6i) has…”
Get full text

Comparison the Efficacy of Second Line Eox and Folfiri Regimens in Metastatic Gastric Cancer by Sendur, M.A., Ozdemir, N., Ozatli, T., Yazici, O., Ekinci, A.S., Yazılıtas, D., Aksoy, S., Oksuzoglu, O.B., Zengin, N.

Get full text

681PCOMPARISON THE EFFICACY OF SECOND LINE EOX AND FOLFIRI REGIMENS IN METASTATIC GASTRIC CANCER by Sendur, M.A., Ozdemir, N., Ozatli, T., Yazici, O., Ekinci, A.S., Yazılıtas, D., Aksoy, S., Oksuzoglu, O.B., Zengin, N.

“…Abstract Aim: Gastric cancer is often diagnosed in advanced stage. Palliative chemotherapy or best supportive care is recommended for patients with metastatic…”
Get full text

298PEFFICACY OF ADJUVANT 9-WEEKS TRASTUZUMAB IN NODE-NEGATIVE T1A/B HER2-POSITIVE BREAST CANCER by Sendur, M.A., Aksoy, S., Uncu, D., Demir, H., Yuksel, S., Ekinci, A.S., Kaplan, M.A., Ustaalioglu, B.B., Tufan, G., İnanc, M., Ozdemir, N., Artac, M., Taştekin, D., Kacan, T., Oguz, A., Arpaci, E., Yazılıtas, D., Gumus, M., Zengin, N., Altundag, M.K.

“…Abstract Aim: The benefit of the addition of 9-weeks or 52-weeks adjuvant trastuzumab to chemotherapy compared with chemotherapy alone was shown in five…”
Get full text

Efficacy of Adjuvant 9-Weeks Trastuzumab in Node-Negative T1A/B Her2-Positive Breast Cancer by Sendur, M.A., Aksoy, S., Uncu, D., Demir, H., Yuksel, S., Ekinci, A.S., Kaplan, M.A., Ustaalioglu, B.B., Tufan, G., İnanc, M., Ozdemir, N., Artac, M., Taştekin, D., Kacan, T., Oguz, A., Arpaci, E., Yazılıtas, D., Gumus, M., Zengin, N., Altundag, M.K.

Get full text